Unfortunately, the solubility of this product is not determined.
SML2475
Larazotide acetate salt
≥95% (HPLC)
別名:
AT-1001, AT1001, GGVLVQPG acetate, Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-glycine acetate
ログイン組織・契約価格を表示する
すべての画像(1)
サイズを選択してください
表示を変更する
5 MG
￥16,200
25 MG
￥67,000
About This Item
実験式（ヒル表記法）:
C32H55N9O10 · xC2H4O2
CAS番号:
分子量:
725.83 (free base basis)
UNSPSCコード:
12352200
NACRES:
NA.77
おすすめの製品
アッセイ
≥95% (HPLC)
フォーム
powder
色
white to beige
輸送温度
wet ice
保管温度
−20°C
SMILES記法
N1([C@@H](CCC1)C(=O)NCC(=O)O)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)CC(C)C)C(C)C)CCC(=O)N.OC(=O)C
InChI
1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(
InChI Key
NYGCNONRVCGHAT-UFIKZEAMSA-N
生物化学的／生理学的作用
Larazotide acetate (AT1001) is a Zonulin receptor antagonist, a tight junction modulator. Larazotide inhibition of zonulin results in reducing trafficking across epithelial cells in the intestines and reducing intestinal permeability and "leaky gut," thought to be a gateway to multiple autoimmune diseases, including celiac disease, irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD, Crohn′s and ulcerative colitis), type 1 diabetes mellitus (T1DM), nonalcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and several others. It has been shown to inhibit the effect of inflammatory cytokines such as tumor necrosis factor (TNF-alpha) and interleukin (IL-4), blocking their increase of intestinal epithelial permeability.
Zonulin receptor antagonist; tight junction modulator
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SML2475-25MG:
SML2475-5MG:
SML2475-VAR:
SML2475-BULK:
最新バージョンのいずれかを選択してください：
Masoumeh Sadat Mousavi Maleki et al.
Amino acids, 55(11), 1601-1619 (2023-10-07)
Enzyme therapy for celiac disease (CeD), which digests gliadin into non-immunogenic and non-toxic peptides, can be an appropriate treatment option for CeD. Here, we have investigated the effectiveness of bromelain and ficin on gliadin digestion using in vitro, such as
Craig Sturgeon et al.
Annals of the New York Academy of Sciences, 1397(1), 130-142 (2017-04-20)
Increased small intestinal permeability (IP) has been proposed to be an integral element, along with genetic makeup and environmental triggers, in the pathogenies of chronic inflammatory diseases (CIDs). We identified zonulin as a master regular of intercellular tight junctions linked
Shahryar Khaleghi et al.
Therapeutic advances in gastroenterology, 9(1), 37-49 (2016-01-16)
Celiac disease (CD) is a common chronic immune disease triggered by gluten. Gliadin peptides pass through the epithelial layers, either paracellularly or transcellularly, to launch a potent adaptive immune response in the lamina propria. This aberrant immune response leads to
Alessio Fasano
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 10(10), 1096-1100 (2012-08-21)
One of the most important and overlooked functions of the gastrointestinal tract is to provide a dynamic barrier to tightly controlled antigen trafficking through both the transcellular and paracellular pathways. Intercellular tight junctions (TJ) are the key structures regulating paracellular
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
